BioSpace News Archive

France-based GenFit launched its $132 million initial public offering plans in order to raise funds that will be used to support the Phase III trial and planned commercialization of its elafibranor compound for non-alcoholic steatohepatitis (NASH).

The scandal, dubbed Operation Varsity Blues, revolves around dozens of wealthy parents paying a college consultant to help cheat on entrance exams and falsify student athlete profiles, as well as bribing coaches at a number of prestigious universities.

As the American College of Cardiology (ACC) annual meeting opens in New Orleans this weekend, one of the big stories will undoubtedly be on the role of wrist sensors, such as the Apple Watch, in identifying heart rhythm problems. There will be other big stories, of course. Here’s a preview of just a couple.

Elizabeth Holmes, the founder of the now-failed Theranos, has become a subject of fascination for many people. Her ability to secure billions of dollars for her company without showing any supporting evidence of the product to investors is a compelling study.

During his relatively brief tenure as Commissioner of the U.S. Food and Drug Administration (FDA), Scott Gottlieb has worked to streamline and advance guidelines for clinical trials. As something of a parting shot, Gottlieb made a statement criticizing the industry’s reluctance to take advantage of them.

The research has broad potential for targeted treatments for neurological diseases like epilepsy or for pain treatment. Their research was published in the journal Science.

The White House budget proposal released earlier this week that slashed spending on the National Institutes of Health and Medicare programs has put members of the administration, including Health and Human Services Secretary Alex Azar on the defensive.

It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.

Are you familiar with the medical writing profession? If not, you could be missing out on one of the most flexible and rewarding careers in life sciences.

Halo Labs Inc. announces that it has agreed to amend the terms of its previously announced “best efforts” offering of convertible debenture units to lower the conversion price at which the convertible debentures are convertible into common shares of the Company from $0.70 per Debenture Share to $0.65 per Debenture Share.